Wall Street analysts expect that Horizon Therapeutics PLC (NASDAQ:HZNP) will announce earnings of $0.39 per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for Horizon Therapeutics’ earnings. The highest EPS estimate is $0.41 and the lowest is $0.37. Horizon Therapeutics posted earnings of $0.48 per share in the same quarter last year, which suggests a negative year over year growth rate of 18.8%. The business is scheduled to announce its next earnings report on Wednesday, August 14th.
According to Zacks, analysts expect that Horizon Therapeutics will report full-year earnings of $1.74 per share for the current fiscal year, with EPS estimates ranging from $1.58 to $1.86. For the next fiscal year, analysts anticipate that the firm will report earnings of $2.05 per share, with EPS estimates ranging from $1.80 to $2.29. Zacks’ earnings per share averages are a mean average based on a survey of research analysts that follow Horizon Therapeutics.
Horizon Therapeutics (NASDAQ:HZNP) last issued its earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.30 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.10 by $0.20. The business had revenue of $280.00 million for the quarter, compared to analyst estimates of $238.35 million. Horizon Therapeutics had a net margin of 3.79% and a return on equity of 33.57%. Horizon Therapeutics’s revenue was up 25.0% on a year-over-year basis. During the same period in the prior year, the firm earned $0.03 earnings per share.
A number of research analysts have weighed in on the stock. BidaskClub lowered shares of Virtu Financial from a “sell” rating to a “strong sell” rating in a research note on Wednesday, June 12th. Mizuho set a $27.00 price objective on shares of Horizon Therapeutics and gave the company a “hold” rating in a research note on Wednesday, May 8th. Piper Jaffray Companies set a $195.00 price objective on shares of Cummins and gave the company a “buy” rating in a research note on Thursday, April 4th. Cantor Fitzgerald raised their price objective on shares of Horizon Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research note on Tuesday, April 2nd. Finally, Citigroup raised their price objective on shares of Martin Marietta Materials from $239.00 to $255.00 and gave the company a “buy” rating in a research note on Wednesday, May 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and ten have issued a buy rating to the company’s stock. Horizon Therapeutics has a consensus rating of “Buy” and a consensus price target of $31.91.
In related news, EVP Vikram Karnani sold 13,111 shares of the firm’s stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $25.02, for a total transaction of $328,037.22. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Jeff Kent sold 3,620 shares of the firm’s stock in a transaction dated Wednesday, June 5th. The shares were sold at an average price of $24.64, for a total transaction of $89,196.80. The disclosure for this sale can be found here. 4.10% of the stock is currently owned by company insiders.
Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Calamos Advisors LLC lifted its position in shares of Horizon Therapeutics by 3.1% during the first quarter. Calamos Advisors LLC now owns 13,400 shares of the biopharmaceutical company’s stock valued at $354,000 after purchasing an additional 400 shares in the last quarter. Creative Planning lifted its position in shares of Horizon Therapeutics by 3.2% during the first quarter. Creative Planning now owns 16,290 shares of the biopharmaceutical company’s stock valued at $431,000 after purchasing an additional 500 shares in the last quarter. American International Group Inc. lifted its position in shares of Horizon Therapeutics by 0.8% during the fourth quarter. American International Group Inc. now owns 110,573 shares of the biopharmaceutical company’s stock valued at $2,161,000 after purchasing an additional 868 shares in the last quarter. Jabodon PT Co. lifted its position in shares of Horizon Therapeutics by 0.8% during the first quarter. Jabodon PT Co. now owns 114,687 shares of the biopharmaceutical company’s stock valued at $3,031,000 after purchasing an additional 895 shares in the last quarter. Finally, Intrust Bank NA lifted its position in shares of Horizon Therapeutics by 6.9% during the first quarter. Intrust Bank NA now owns 15,666 shares of the biopharmaceutical company’s stock valued at $414,000 after purchasing an additional 1,008 shares in the last quarter. 87.79% of the stock is currently owned by institutional investors.
Shares of NASDAQ HZNP opened at $23.46 on Tuesday. Horizon Therapeutics has a 12-month low of $16.56 and a 12-month high of $29.44. The company has a market capitalization of $4.34 billion, a price-to-earnings ratio of 12.82, a PEG ratio of 1.35 and a beta of 1.03. The business’s fifty day moving average is $23.99. The company has a debt-to-equity ratio of 0.90, a quick ratio of 1.68 and a current ratio of 1.74.
Horizon Therapeutics Company Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Featured Story: Understanding Average Daily Trade Volume
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.